Cytodyn Inc (CYDY)

[GreenBioAnalyst]

About #CYDY 's Leronlimab...A statistical p-value of <.05 in mortality rate is the surrogate endpoint for a long-term outcome to stop the trial, and it could be the reason why they're doing a presentation? Instead of releasing the pr without the call ?NP loves to make a splash so no way on earth he'll skip the WEBCAST to tell the world that DSMC STOPPED the trial based on interim analysis for efficacy of survival vs mortality rate in placebo? ??????
I doubt it's about safety or toxicity issues on Leronlimab, so it has to be on the efficacy side since we are looking for clear clinical benefits on the survival rate over the mortality rate on the placebo group. Now, if this was a bad news, they would have released this same outcome just like what they did on the REMDESIVIR'S study in China last spring. dadada! Tat! Tat! at!
Conclusion: Stat significant! And DSCM stopping the trial to address this unmet medical needs in saving SEVER&CRITICALLY ILL PATIENTS!